[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540803":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":14,"centralContacts":19,"locations":24,"responsibleParty":66,"collaborators":10,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":10,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Azienda Usl di Bologna","OTHER_GOV",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"retrospective cohort",null,"patients with a diagnosis of new-onset neurocognitive disorders (major and minor) with onset within the previous 24 months",{"label":13,"type":10,"description":11,"interventionNames":10},"prospective cohort",[15],{"name":16,"affiliation":17,"role":18},"Maria Pia Giannoccaro, Dr.","IRCCS Istituto delle Scienze Neurologiche di Bologna","PRINCIPAL_INVESTIGATOR",[20],{"name":16,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","+390514966112","mariapia.giannoccaro@ausl.bologna.it",[25,40,55],{"facility":17,"status":26,"city":27,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Bologna","40139","Italy","IT",{"type":32,"coordinates":33},"Point",[34,35],11.33875,44.49381,{"lat":35,"lon":34},[38],{"name":16,"role":21,"phone":39,"phoneExt":10,"email":23},"0514966117",{"facility":41,"status":26,"city":42,"state":43,"zip":44,"country":29,"countryCode":30,"cosmosGeoPoint":45,"geoPoint":49,"contacts":50},"Istituto Auxologico Italiano IRCCS","Milan","Milano","20095",{"type":32,"coordinates":46},[47,48],12.59836,42.78235,{"lat":48,"lon":47},[51],{"name":52,"role":21,"phone":53,"phoneExt":10,"email":54},"Federico Verde, Dr.","+3902619112247","f.verde@auxologico.it",{"facility":56,"status":26,"city":42,"state":43,"zip":57,"country":29,"countryCode":30,"cosmosGeoPoint":58,"geoPoint":60,"contacts":61},"Fondazione IRCCS Istituto Neurologico Carlo Besta","20133",{"type":32,"coordinates":59},[47,48],{"lat":48,"lon":47},[62],{"name":63,"role":21,"phone":64,"phoneExt":10,"email":65},"Chiara Maria Giulia De Luca, Dr.","+390223942498","chiara.deluca@istituto-besta.it",{"type":67,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100540803","autoimmune-dementia-predictors-of-neuronal-synaptic-antibodies-in-patients-with-new-onset-cognitive-impairment-100540803",false,"NCT06321588","Autoimmune Dementia: Predictors of Neuronal Synaptic Antibodies in Patients With New-ONset Cognitive Impairment","Autoimmune Dementia: Predictors of Neuronal Synaptic Antibodies in Patients With New-ONset Cognitive Impairment and Their Relevance in Non-encephalitic formS: The ADONIS Study","ADONIS","Inclusion Criteria:\n\n* both sexes\n* adult (aged between 40 and 90 years)\n* patients with a diagnosis of new-onset neurocognitive disorders (major and minor), as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, with onset within the previous 24 months\n\nExclusion Criteria:\n\n\\- presence of a history of seizures within 4 weeks from onset.","ALL","40 Years","90 Years",{"count":80,"type":81},300,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to investigate the frequency and the possible pathogenic role of neuronal synaptic antibodies (NSAb) in patients with cognitive impairment (CI). The main questions it aims to answer are:\n\n1. the frequency and associated features of NSAb in patients with CI and the usefulness of a clinical score in improving autoimmune dementia (AID) diagnosis;\n2. the clinical significance of NSAb in patients with CI not fulfilling the autoimmune encephalitis (AE) criteria and serum NSAb (NSAb-pos-CI);\n3. the impact of blood-brain-barrier (BBB) dysfunction on their pathogenicity.",[85,86],"Cognitive Impairment","Dementia","2026-02-09",{"date":89,"type":90},"2026-02-11","ACTUAL",{"date":92,"type":90},"2023-05-10",{"date":94,"type":81},"2026-06-30",{"name":5,"class":6},3]